<?xml version="1.0" encoding="UTF-8"?>
			<!DOCTYPE ijpp.edwiserinternational.com [
<!ELEMENT channel (title,link,description,language,managingEditor,webMaster,copyright,image,item,item,item,item,item)>
<!ELEMENT title (#PCDATA)>
<!ELEMENT link (#PCDATA)>
<!ELEMENT language (#PCDATA)>
<!ELEMENT managingEditor (#PCDATA)>
<!ELEMENT webMaster (#PCDATA)>
<!ELEMENT copyright (#PCDATA)>

<!ELEMENT image (title,link,url,width,height)>
<!ELEMENT url (#PCDATA)>
<!ELEMENT width (#PCDATA)>
<!ELEMENT height (#PCDATA)>

<!ELEMENT item (title,pubDate,link,author,comments,category,description)>
<!ELEMENT pubDate (#PCDATA)>
<!ELEMENT author (#PCDATA)>
<!ELEMENT comments (#PCDATA)>
<!ELEMENT category (#PCDATA)>
<!ELEMENT description (#PCDATA)>

]>
		<channel>
<title>Journal-of-Pharmaceutical-Research-Science-Technology-ISSUE VOLUME Volume 8 ISSUE Issue 2</title>
<link>http://ijpp.edwiserinternational.com/rss-feed.php</link>
<description>
Journal-of-Pharmaceutical-Research-Science-Technology: VOLUME Volume 8 ISSUE Issue 2, July-Dec 2024
</description>
<language>en-us</language>
<managingEditor>editor@edwiserinternational.com</managingEditor>
<webMaster>editor@edwiserinternational.com</webMaster>
<copyright>editor@edwiserinternational.com</copyright>
<image>
<title>Journal-of-Pharmaceutical-Research-Science-Technology-ISSUE VOLUME Volume 8 ISSUE Issue 2</title>
<link>http://ijpp.edwiserinternational.com/rss-feed.php</link>
<url>http://ijpp.edwiserinternational.com/img/logo1.png</url>
<width>360</width>
<height>109</height>
</image><item>
		<title>Observational-study-of-twenty-diabetic-patients-using-the-combination-of-Diabetes-free-and-Pancreas-free-remedies-from-an-Ivorian-traditional-healer</title>
		<pubDate>14-May-2025</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/xdcLjZ.pdf</link>
		<author>Effo-KE-Matto-Y-Adehouni-YA-et-al-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[As a response to the adverse effects and high cost of conventional anti-diabetic drugs, traditional medicine seems to be an alternative for local populations. The objective of this study was to carry out a biological and clinical follow-up of diabetic patients using the Diabete free and Pancreas free combination remedies from an Ivorian traditional healer. A cross-sectional observational study was conducted on twenty (20) diabetic patients using the Diabetes free and Pancreas free combination remedies from August 2023 to February 2024. A questionnaire was filled in by volunteer patients. Weekly fasting capillary blood glucose levels were monitored. A clinical follow up was also used to identify adverse effects. Patients were 70% female and 30% male. 85% suffered from type 2 diabetes. Diabetes was a family trait in 70% of cases. Mean blood glucose at diagnosis was 2.200.77 g/l. Diabetes Free and Pancreas Free are tablets made from medicinal plants. The dosage was one tablet (if blood glucose was between  [1.26-1.60] g/l) or 2 tablets (if blood glucose was > 1.60 g/l), to be repeated once daily. A weekly mean reduction in blood glucose of 0.070.03g/l was observed. The mean blood glucose at week 12 was 0.920.15g/l. Adverse effects were characterized by anorexia (55%), dizziness (60%) and digestive disorders (20%). Diabetes Free and Pancreas Free could significantly help  in reducing glycaemia, with adverse effects at beginning of treatment. However, further studies need to be done.]]>}</description>
		</item><item>
		<title>Isolation-Structural-Elucidation-and-Anti-inflammatory-Studies-In-vitro-in-silico-on-the-Fruit-Extract-of-Sarcocephalus-latifolius-Sm-Bruce</title>
		<pubDate>14-May-2025</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/kYKc53.pdf</link>
		<author>Yesufu-HB-Ukwubile-CA-Milagawanda-HH-et-al-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[The quest for novel therapeutic agents from natural sources has led to a burgeoning interest in medicinal plants, particularly those used in traditional medicine. S. latifolius, a member of the Rubiaceae family, has attracted attention due to its diverse phytochemical composition and documented medicinal properties. The Plant material was extracted with ethanol (Soxhlet method) and then fractionated with n-hexane. The fractions (n-hexane and residual aqueous) were evaluated via in-vitro assays (DPPH assay, Egg albumin and Histamine). The most active fraction (n-hexane) was subjected to GC-MS analysis and further isolation protocol. The results showed moderate to good free radical scavenging potential with IC50= 0.33 (n-hexane) and IC50= 0.55 (residual aqueous) when compared to the standard ascorbic acid IC50= 056. Also, higher inhibition of histamine induced inflammation (In-vitro) was recorded by the extracts at 200 mg and 400 mg while inhibition of the egg-albumin induced inflammation (in-vitro) was recorded at 200 mg when compared to the standard drug (acetic acid). The binding potential of the compounds to the Pro-inflammatory receptor used (TNF-1) showed favorable interaction and inhibition of the Pro-inflammatory cytokine. The isolated compound (naucline) which hither-to has been reported from other parts of the plant except the fruit also showed good binding affinity to the inflammatory receptor. Our study showed that the isolation and structural elucidation of phytochemicals from S. latifolius fruits revealed a complex tapestry of bioactive compounds with significant therapeutic potential. Hence, the need for clinical trials to substantiate the traditional uses of S. latifolius and explore its full pharmacological potential.]]>}</description>
		</item><item>
		<title>Biological-Profiling-of-Two-New-Vanillyl-Schiff-Bases</title>
		<pubDate>14-May-2025</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/DH42gW.pdf</link>
		<author>Oladimeji-OH-Uduak-SJ-Sunday-NC-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Background: Schiff bases are a class of organic compounds referred to as imines and characterised by a carbon-nitrogen double bond. Their versatility and exhibition of a broad spectrum of biological activities such as antioxidant, antibacterial, antifungal, antiviral, anti-malarial, anti-inflammatory and anticancer amongst many others contribute to their significance in organic chemistry. Objectives: The harmful effects of free radicals to the human body and the ever worrisome  prevalence of microbial resistance to anti-infective drugs currently in clinical therapy led to the search for new molecules with possibly better activities for treating/ameliorating disease conditions. This search for novel pharmaceutically active compounds with the aim of mitigating these conditions threw up the choice of Schiff base synthesis using vanillin and two alkyl amines.  Methodology: Vanillin was reacted separately with these amines leading to Schiff bases in the presence of acid. The melting points, refractive indices and optical rotations of the vanillin and the resultant bases were obtained. The antioxidant activity (IC50) of these compounds was evaluated using the DPPH (2, 2-diphenyl-1-picrylhydrazyl hydrate) assay test. A comparison of the antioxidant activities so obtained was done to determine if the synthesized bases would show better activities than vanillin and Vitamin C. The agar diffusion method was adopted for screening the compounds against Staphylococcus aureus, Escherichia coli and Candida albicans for both antibacterial and antifungal potentials respectively.  Results: A combination of physico-chemical determinations and IR spectral technique have revealed that both synthesized imines are new. Consequently, their nomenclatures are vanillyl hexyl imine (1-iminohexyl-3-methoxy-4-hydroxy benzene)  (Iyadimine A) and vanillyl heptyl imine (1-iminoheptyl-3-methoxy-4-hydroxy benzene) (Iyadimine B ) respectively. Vanillin  demonstrated  a moderate antioxidant activity of IC50  of  0.52 g/mL which compare favourably with 0.48 g/mL shown by Vitamin C. However, both Iyadimine A and Iyadimine B were marginally active at 1.93 and 1.03 g/mL respectively. Interestingly, Iyadimine B was slightly more antioxidant on account of the longer heptyl chain which makes it more lipophillic than Iyadimine A with the hexyl moiety rendering it less lipophillic.  Both the antibacterial and antifungal activities elicited by the imines showed concentration-dependency. Furthermore, Iyadimine A was more antibacterial against S. aureus than  E. coli while the converse was observed with  Iyadimine B. However both were remarkably suppressive of C. albicans. Conclusion: The results from this study indicate that two newly synthesized vanillyl imines  demonstrated marginal antioxidant activities. Furthermore both bases also showed good antibacterial and antifungal activities.  Hence, the two compounds could be promising lead drug templates in the search for newer and more efficacious biological agents especially in synergistic antimicrobial co-administration and formulation studies in drug development.]]>}</description>
		</item><item>
		<title>Guillain-Barr-Syndrome-A-Silent-Threat-to-Our-Nervous-System</title>
		<pubDate>14-May-2025</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/Y2yxb4.pdf</link>
		<author>Jahangir-MA</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Guillain-Barr Syndrome (GBS) is a rare but potentially life-threatening condition that occurs when the bodys immune system mistakenly attacks the peripheral nervous system. This disorder often follows a viral or bacterial infection, with many patients reporting the onset of symptoms after recovering from a respiratory or gastrointestinal infection. Though it is not well-known in the general public, GBS holds significant implications for public health due to its ability to strike swiftly, paralyze, and potentially lead to long-term disability.]]>}</description>
		</item><item>
		<title>Acute-Encephalitis-Syndrome-The-Lethal-Hazard-of-Chandipura-Virus</title>
		<pubDate>14-May-2025</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/UX5xhD.pdf</link>
		<author>Kamran-Ahmad</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Acute Encephalitis Syndrome (AES) is a critical and frequently fatal syndrome marked by the swift development of cerebral inflammation, resulting in symptoms including fever, disorientation, seizures, and, in severe instances, irreversible neurological impairment or mortality. The Chandipura virus (CHPV), a lesser known yet perilous infection, has surfaced as a notable cause of AES in specific regions of India, despite many viruses being recognised as responsible for the condition. This virus, chiefly spread by mosquitoes, poses a multifaceted and developing challenge to public health, with its severe repercussions frequently intensified by delayed diagnosis and treatment.]]>}</description>
		</item></channel>